Finance

Lists
PTKFY:OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
8,50 $
0,00%
(0,00) 1D
12 қаз., 10:22:09 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTKFY...
Mkt. cap
31,60 трлн
Avg. vol.
1,94 мың
Volume
1,43 мың
52-wk high
16,36 $
52-wk low
7,63 $
Beta
0,09
Shares outstanding
234,07 млн
No. of employees
13 мың
Mkt. cap
31,60 трлн
Avg. vol.
1,94 мың
Volume
1,43 мың
52-wk high
16,36 $
52-wk low
7,63 $
Beta
0,09
Shares outstanding
234,07 млн
No. of employees
13 мың
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About PT Kalbe Farma Unsponsored Indonesia ADR
CEO-
Employees12,8 мың
Founded1966 ж. 10 қыр.
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
8,91 трлн
9,34 трлн
9,68 трлн
9,80 трлн
Cost of goods sold
5,46 трлн
5,92 трлн
6,02 трлн
6,25 трлн
Cost of revenue
5,46 трлн
5,92 трлн
6,02 трлн
6,25 трлн
Research and development expenses
98,31 млрд
160,88 млрд
113,14 млрд
122,60 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 трлн
1,95 трлн
2,23 трлн
2,27 трлн
Operating expense
2,60 трлн
2,14 трлн
2,33 трлн
2,39 трлн
Total operating expenses
8,06 трлн
8,05 трлн
8,36 трлн
8,64 трлн
Operating income
851,77 млрд
1,28 трлн
1,32 трлн
1,16 трлн
Other non operating income
-3,78 млрд
-4,17 млрд
-3,63 млрд
-3,74 млрд
EBT including unusual items
877,87 млрд
1,30 трлн
1,36 трлн
1,19 трлн
EBT excluding unusual items
888,55 млрд
1,30 трлн
1,36 трлн
1,18 трлн
Income tax expense
211,19 млрд
252,81 млрд
303,84 млрд
271,57 млрд
Effective tax rate
24,06%
19,41%
22,40%
22,80%
Other operating expenses
-7,23 млрд
31,35 млрд
-10,02 млрд
2,13 млрд
Net income
656,41 млрд
1,03 трлн
1,03 трлн
890,54 млрд
Net profit margin
7,37%
11,07%
10,63%
9,09%
Earnings per share
14,44
22,72
22,74
19,68
Interest and investment income
41,31 млрд
40,43 млрд
32,07 млрд
43,61 млрд
Interest expense
-9,69 млрд
-5,77 млрд
-4,61 млрд
-6,78 млрд
Net interest expenses
31,62 млрд
34,66 млрд
27,46 млрд
36,83 млрд
Depreciation and amortization charges
-
-
-
-
EBITDA
1,05 трлн
1,45 трлн
1,51 трлн
1,20 трлн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары